Protocol Ledger

NCT06979375 · Phase II · RECRUITING

A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

Interventional Phase II clinical trial protocol NCT06979375 sponsored by Novo Nordisk in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-06-30 Enrollment: 200 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06979375
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)200 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06979375
Protocol FieldVerified Registry Value
NCT IdentifierNCT06979375
Consolidated Lead SponsorNovo Nordisk
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment200 participants (ESTIMATED)
Registered Start Date2025-06-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06979375
Hospital Research SiteLocationSite Profile
Flinders Medical CentreBedford Park, AustraliaOpen Hospital Dossier ->
Royal Hobart HospitalHobart, AustraliaOpen Hospital Dossier ->
Vseobecna fakultni nemocnice v PrazePrague, CzechiaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI